Wockhardt Q2 FY27 Share Price & Earnings Call Analysis

Part of: Nifty Smallcap 250 · Nifty Pharma · Nifty Smallcap 50 · NIFTY Smallcap 100 · Nifty MidSmallcap 400 · Nifty 500 · +1 more

₹2,006.30-2.15% today
Market cap
₹32,620 Cr
P/E
81.61
ROE
6.11%
PEG
1.88
Price to sales
8.70
Debt to equity
0.43
52W high / low
₹2,330 / ₹1,100
Sales growth (5Y)
4.49%
EBITDA margin
20.45%
Net profit margin
8.01%
Promoter holding
49.33%
Sales (last year)
₹3,751 Cr

Wockhardt is a global pharmaceutical and biotechnology organization engaged in manufacturing finished dosage formulations, injectables, biopharmaceuticals, orals and topicals (creams and ointments). [1]

Guidance scorecard · Q2 FY27 call

What Wockhardt's management guided
and where it ranks in Pharmaceuticals & Biotechnology

#18of 87 in
Pharmaceuticals & Biotechnology

RevenueQ4 FY26 call

20–40%
  • Slow initial increase in revenue from new molecules like Zaynich, with a hockey-stick growth trajectory expected after 12-18 months.
  • Significant market share goal of about 20-25% of resistant cases long-term.
  • Biosimilar business to double within 24 to 36 months driven by capacity expansion and pipeline product launches.
  • Capex of INR 200-300 crores planned over next three years, mainly in biologicals capacity.
  • Initial 12-18 months of slight loss or neutral profitability expected during market organization establishment for Zaynich, followed by strong profitability growth.
  • Overall company growth inherent due to multiple molecules without needing acquisitions.
  • India biosimilar market opportunity estimated at $6-7 billion.

2 more points from Wockhardt's call on revenue

Create a free account to keep reading this call

Full Q4 FY26 analysis

MarginsQ4 FY26 call

Flat

See what Wockhardt said on margins — free account, 30 seconds.

Full Q4 FY26 analysis

CapexQ4 FY26 call

Planned
  • Planned capex over next three years: INR 200 to 300 crores, mainly for expanding biologicals capacity.
  • Investment in increasing biosimilar capacity, aiming to double capacity within 12 to 15 months.
  • Continued R&D spends at a consistent percentage of sales to support product pipeline development.
  • Focus on building a new business model and organizational capabilities for commercialization of innovative drugs like Zaynich, involving upfront revenue costs rather than capex.

2 more points from Wockhardt's call on capex

Create a free account to keep reading this call

Full Q4 FY26 analysis

FundraisingQ4 FY26 call

See what Wockhardt said on fundraising — free account, 30 seconds.

Full Q4 FY26 analysis

Order bookQ4 FY26 call

Ask what Wockhardt said on the order book →

Full Q4 FY26 analysis

Ranges are what management guided for revenue growth and margins on the latest earnings call. Not investment advice, and not a forecast of returns.

Potential multibaggers · Q2 FY27

Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance

  1. Strong growth
    2
  2. Strong growth
    1
  3. 3

Portfolio builder

Build your portfolio
from the top-ranked stocks

  1. 1. Pick 3–15 stocks
  2. 2. Choose large, mid or small cap and your sectors
  3. 3. Get a portfolio built from the rankings
Build my portfolio

Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.

Peers

Pharmaceuticals & Biotechnology companies ranked on guidance

#CompanyRevenue guidedMargin guidedMarket capP/E
140%+Up 2%+₹480 Cr19.1
240%+Up 0–2%₹212 Cr16.1
340%+Flat₹18,347 Cr—
440%+Flat₹8,418 Cr32.3
540%+Flat₹4,268 Cr—
640%+Flat₹40 Cr—

Financials of Wockhardt

Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.

Shareholder Pattern

Wockhardt

Shareholding breakup across reporting periods.

Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
Promoters +54.93%51.60%51.99%51.99%49.09%49.09%49.09%49.09%49.09%49.09%49.09%49.33%
FIIs +4.18%5.49%5.94%6.70%6.54%6.82%7.29%7.10%7.00%7.09%7.23%7.02%
DIIs +0.30%4.82%4.45%5.08%9.82%10.58%11.00%11.00%10.55%10.96%9.24%9.00%
Government +0.00%0.01%0.01%0.02%0.02%0.02%0.02%0.02%0.02%0.04%0.02%0.01%
Public +40.59%38.06%37.62%36.21%34.54%33.50%32.60%32.79%33.36%32.84%34.44%34.64%
No. of Shareholders1,61,8131,46,1381,40,3911,38,1421,42,7101,41,7991,46,9181,37,9461,42,2741,39,0161,66,5181,73,116

Pros & Cons

Wockhardt

Key positives and risks surfaced from the company insights section.

Pros
  • Stock is trading at 5.98 times its book value
  • The company has delivered a poor sales growth of 4.49% over past five years.
  • Company has a low return on equity of -1.43% over last 3 years.
  • Promoter holding has decreased over last 3 years: -5.81%
Raw Insights
  • Stock is trading at 5.98 times its book value
  • The company has delivered a poor sales growth of 4.49% over past five years.
  • Company has a low return on equity of -1.43% over last 3 years.
  • Promoter holding has decreased over last 3 years: -5.81%

Financials of Wockhardt

Quarterly Results

Quarter-by-quarter operating performance

Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
Sales +753701700739809721743738782888965929969
YoY Sales growth+11%+0%+3%+15%+7%+3%+6%-0%-3%+23%+30%+26%+24%
Expenses +681664759648699593679666604711740737796
Operating Profit7237-59911101286472178177225192173
OPM %10%5%-8%12%14%18%9%10%23%20%23%21%18%
Other Income +24810309815-772115673111
Interest76777373736048485560505256
Depreciation55555854555553565365535555
Profit before tax-35-87-180-6-921-22-109916718911673
Tax %109%-1%-2%167%78%5%105%-1%10%9%13%8%0%
Net Profit +-73-86-177-16-1620-45-108826116410773
EPS in Rs-5.34-5.76-11.02-0.91-1.430.86-1.54-5.544.803.6310.226.524.86

Financials of Wockhardt

Profit & Loss

Annual income statement trend

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales +4,4824,4534,0153,9373,5662,8442,7083,2302,6512,7983,0123,3733,751
Sales growth-7%-1%-10%-2%-9%-20%-5%+19%-18%+6%+8%+12%+26%
Expenses +3,7723,9594,0023,9353,6042,7252,7712,9322,5492,7072,6192,7212,984
Operating Profit709494132-38119-6329810291393652767
OPM %16%11%0.3%0.1%-1.1%4.2%-2.3%9%3.9%3.2%13%19%20%
Other Income +6766114-238116133975-163-173176226124
Interest55129225255265276249299302305254213218
Depreciation145142149150164224246247251223217227228
Profit before tax575289-247-641-351-247417-411-624-420-16238445
Tax %28%13%-9%4%-38%-82%-65%-32%-0%12%256%16%
Net Profit +413252-226-667-217-43688-279-621-472-57199405
EPS in Rs33.9120.91-16.32-50.69-16.20-5.7657.07-16.94-38.80-30.18-2.8913.1125.23
Dividend Payout %54%0%-56%0%0%0%0%0%0%0%0%0%

Financials of Wockhardt

Balance Sheet

Capital structure and asset base

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Sep 2026
Equity Capital55555555555555727277818181
Reserves3,3623,7203,2812,7972,6192,6163,3213,7773,2823,2824,2724,8595,077
Borrowings +2,3092,6774,1603,7483,3753,5822,6742,1982,1842,3562,0212,2332,238
Other Liabilities +1,2131,6221,4861,5281,7641,8941,6962,1682,1131,8991,7261,4051,506
Total Liabilities6,9398,0748,9828,1287,8138,1487,7468,2157,6517,6148,1008,5788,902
Fixed Assets +2,1232,8092,7732,8883,0583,5023,3433,4623,0422,8812,7362,7914,655
CWIP1,0071,0361,2441,4331,4451,5851,3791,3421,5391,7222,0332,379676
Investments3410563214000000422412117
Other Assets +3,4684,2284,4033,5933,3093,0603,0243,4113,0703,0112,9092,9963,454
Total Assets6,9398,0748,9828,1287,8138,1487,7468,2157,6517,6148,1008,5788,902

Financials of Wockhardt

Cash Flows

Operating, investing and financing cash movement

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from Operating Activity +355-42-26968183649-287413153219-22390
Cash from Investing Activity +-222-105-68463593-1471,471-204-118-138-780-231
Cash from Financing Activity +-761931,254-769-776-680-1,171-71-315334409-54
Net Cash Flow5746301-66-500-17813138-280415-393105
Free Cash Flow-76-105-678-238127486-4522022369-37776
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit73%-8%-1,887%4,697%-583%560%270%171%161%274%-13%63%

Financials of Wockhardt

Ratios

Working capital efficiency and return ratios

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days60919489130159124104110818064
Inventory Days250249243174183209256222216201234286
Days Payable136144117122187272223265285240191182
Cash Conversion Cycle17519622014112697157604141123168
Working Capital Days145236-56-51-171-133-116-186-163-2335
ROCE %10%7%-1%-1%-1%-1%-3%1%-0%-1%4%8%

Guidance history

How Wockhardt's guidance has moved, call by call

CallRevenueMarginsCapexFundraisingOrder book
Q4 FY26 call →20–40%FlatPlanned——
Q4 FY25 call →20–40%FlatPlannedPlanned—
Q3 FY23 call →20–40%Up 2%+PlannedPlanned—

What management guided on each call, newest first. Not investment advice, and not a forecast of returns.

75out of 100

Momentum score · price trend

75 out of 100 — Strengthening

Over the past year its share price has done better than most of the stocks we track.

PeriodShare price changeBetter than … of 1,920 stocks
Last 12 months+43.9%82%
Last 6 months+21.2%77%
Last 3 months−3.7%55%
How we calculate it

“Better than 30%” means that over that period the share price did better than 30 out of every 100 stocks we track (1,920 Indian companies worth ₹500 Cr or more, with at least a year of prices).

The score weighs the longer periods more: 40% × 12-month + 40% × 6-month + 20% × 3-month. For Wockhardt: 0.4 × 82 + 0.4 × 77 + 0.2 × 55 = 75.

Strengthening is 70 and above, Steady 40 to 70, Cooling below 40. Scores are recalculated every night after the market closes.

Full methodology →

This describes only how the share price has moved up to 6 Nov 2026, compared with other stocks. It says nothing about the business, and it is not a prediction, a price target or a recommendation to buy or sell.

Others in Pharmaceuticals & Biotechnology this season

  • Divis Laboratories (Q2 FY27)

    Consolidated total income: ₹3770 crores . Key results statement takeaways from Divis Laboratories Ltd's Q2 FY27 results statement — and how it ranks against sec

  • Infinium Pharma (Q2 FY27)

    3,940.98 Lacs (about 54.3% increase) . Key results statement takeaways from Infinium Pharmachem Ltd's Q2 FY27 results statement — and how it ranks against secto

  • Walpar Nutrition (Q2 FY27)

    3,631.14 Lakhs for the half year ended September 30, 2025, reflecting a year-on-year increase of approximately 13.79%. Key results statement takeaways from Walp

  • Kilitch Drugs (Q2 FY27)

    14.3%) . Key results statement takeaways from Kilitch Drugs (India) Ltd's Q2 FY27 results statement — and how it ranks against sector peers.